Baillie Gifford & Co’s Pfizer PFE Stock Holding History

Baillie Gifford & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-466	Closed	-$19K	–	400
2023 Q1	$19K	Hold	466	–	–	﹤0.01%	345
2022 Q4	$23.9K	Hold	466	–	–	﹤0.01%	328
2022 Q3	$20K	Sell	466 -34	-7%	-$1.65K	﹤0.01%	335
2022 Q2	$26K	Hold	500	–	–	﹤0.01%	320
2022 Q1	$26K	Hold	500	–	–	﹤0.01%	337
2021 Q4	$30K	Hold	500	–	–	﹤0.01%	331
2021 Q3	$22K	Buy	+500	New	+$22.1K	﹤0.01%	360
2014 Q4	–	Sell	-359,069	Closed	-$10.1M	–	213
2014 Q3	$10.1M	Sell	359,069 -2,587,663	-88%	-$72.6M	0.02%	148
2014 Q2	$83M	Sell	2,946,732 -1,904,942	-39%	-$54.3M	0.18%	82
2014 Q1	$148M	Sell	4,851,674 -47,011	-1%	-$1.4M	0.35%	64
2013 Q4	$142M	Sell	4,898,685 -142,201	-3%	-$4.14M	0.34%	62
2013 Q3	$137M	Buy	5,040,886 +296,378	+6%	+$8.06M	0.35%	61
2013 Q2	$126M	Buy	+4,744,508	New	+$131M	0.38%	57

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baillie Gifford & Co's PFE Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Pfizer (PFE) in Q2 2023, closing a stake of 466 shares — an estimated $19K sold.

Baillie Gifford & Co first reported a position in PFE in Q2 2013 and held it in 13 quarters. The position peaked at $148M in Q1 2014. 3,041 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

Baillie Gifford & Co reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
Baillie Gifford & Co sold 466 Pfizer shares in Q2 2023, an estimated $19K.
Baillie Gifford & Co first reported a position in Pfizer in Q2 2013 and held it in 13 quarters.
Baillie Gifford & Co's Pfizer position peaked at $148M in Q1 2014.
3,041 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.